- Home
- PIM vs MSLE Comparison
PIM vs MSLE Comparison
Compare PIM & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PIM | MSLE |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | Canada |
| Employees | N/A | 21 |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 154.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PIM | MSLE |
|---|---|---|
| Price | $3.19 | $9.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 44.0K | ★ 63.2K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $64.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.07 | $5.44 |
| 52 Week High | $3.50 | $13.39 |
Technical Indicators
Market Signals| Indicator | PIM | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 75.47 |
| Support Level | $3.14 | $6.71 |
| Resistance Level | $3.24 | $13.39 |
| Average True Range (ATR) | 0.03 | 0.68 |
| MACD | 0.00 | 0.35 |
| Stochastic Oscillator | 70.00 | 91.12 |
Price Performance
Historical ComparisonAbout PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.